Skip to Content

Susan Schneider Thomas

Shareholder
P: 215.875.5711
F: 215.875.4604
sthomas@bm.net Download vCard

Susan Schneider Thomas is a shareholder in the Consumer Fraud and Whistleblower/Qui Tam practice groups at Berger & Montague.  She concentrates her practice on qui tam litigation.

Ms. Thomas has substantial complex litigation experience.  Before joining Berger & Montague, she practiced law at two Philadelphia area firms, Schnader, Harrison, Segal & Lewis and Greenfield & Chimicles, where she was actively involved in the litigation of complex securities fraud and derivative actions.

Upon joining Berger & Montague, Ms. Thomas concentrated her practice on complex securities and derivative actions.  In 1986, she joined in establishing Zlotnick & Thomas where she was a partner with primary responsibility for the litigation of several major class actions including Geist v. New Jersey Turnpike Authority, C.A. No. 92-2377 (D.N.J.), a bond redemption case that settled for $2.25 million and Burstein v. Applied Extrusion Technologies, C.A. No. 92-12166-PBS (D. Mass.), which settled for $3.4 million.

Upon returning to Berger & Montague, Ms. Thomas has had major responsibilities in many securities and consumer fraud class actions, including In re CryoLife Securities Litigation, C.A. No. 1:02-CV-1868 BBM (N.D.Ga.), which settled in 2005 for $23.25 million and In re First Alliance Mortgage Co., Civ. No. SACV 00-964 (C.D.Cal.), a deceptive mortgage lending action which settled for over $80 million in cooperation with the FTC.  More recently, Ms. Thomas has concentrated her practice in the area of healthcare qui tam litigation. As co-counsel for a team of whistleblowers, she worked extensively with the U.S. Department of Justice and various State Attorney General offices in the prosecution of False Claims Act cases against pharmaceutical manufacturers that recovered more than $2 billion for Medicare and Medicaid programs and over $200 million for the whistleblowers. She has investigated or is litigating False Claims Act cases involving defense contractors, off-label marketing by drug and medical device companies, federal grant fraud, upcoding and other billing issues by healthcare providers, drug pricing issues and fraud in connection with for-profit colleges and student loan programs.